10-Q: Zymeworks Reports Strong Q2 Revenue Growth, Narrows Loss

Zymeworks Inc. reported a significant increase in Q2 2025 revenue and a substantial reduction in net loss, driven by key milestone payments and initial royalties from its partnered zanidatamab program.

Summary

• Revenue from research and development collaborations increased by 153.2% to $48.7 million for the three months ended June 30, 2025, compared to $19.2 million in the same period of 2024.
• The company achieved a net income of $2.3 million for Q2 2025, a significant improvement from a net loss of $37.7 million in Q2 2024.
• For the six months ended June 30, 2025, revenue increased by 159.1% to $75.8 million, up from $29.3 million in the prior year period.
• Net loss for the six months ended June 30, 2025, significantly narrowed to $20.3 million, compared to a net loss of $69.3 million for the same period in 2024.
• Key revenue drivers in Q2 2025 included a $7.5 million option exercise fee from BMS, a $20.0 million milestone payment from BeOne for conditional approval of zanidatamab in China, and $18.3 million in recognized deferred revenue related to this milestone.
• Total cash resources, including cash, cash equivalents, and marketable securities, stood at $333.4 million as of June 30, 2025.
• The company anticipates its existing cash resources will fund operating and capital expenditures for at least the next twelve months.
• Zanidatamab received conditional marketing authorization from the European Commission in July 2025 for HER2+ BTC and conditional approval from the NMPA in China in May 2025 for the same indication.
• A Phase 2 trial (EmpowHER-BC-208) for zanidatamab in HER2-positive neoadjuvant and adjuvant breast cancer was initiated in August 2025.
• The IND application for ZW251, a GPC3-targeting ADC, was cleared by the FDA in July 2025, with Phase 1 clinical studies planned for 2025.
• The company is evolving its business strategy to focus on anticipated royalty and milestone revenues from Ziihera, supplemented by new partnerships and opportunistic investments, aiming for a capital-efficient partnership model.
• Development of ZW220, an ADC targeting NaPi2b, has been paused to accelerate ZW251, though ZW220 remains an IND-ready asset.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant financial improvements (revenue growth, reduced losses, Q2 profitability) driven by key milestone achievements and initial royalty revenues from partnered programs. Multiple regulatory authorizations for zanidatamab and IND clearance for a new wholly-owned asset demonstrate strong pipeline progression. The strategic shift towards a capital-efficient, partnership-driven model is a prudent move for long-term sustainability. However, the company still faces substantial future funding needs, inherent risks of clinical development, and the pausing of one pipeline asset, which temper the overall positive outlook.

Positives

• Achieved net income of $2.3 million in Q2 2025, a substantial turnaround from a $37.7 million net loss in Q2 2024.
• Reported a 153.2% increase in Q2 2025 revenue, reaching $48.7 million, primarily due to significant milestone payments.
• Secured conditional marketing authorization for Ziihera (zanidatamab) in Europe and conditional approval in China for HER2+ BTC, expanding market reach.
• Received a $20.0 million milestone payment from BeOne and recognized $18.3 million in deferred revenue following zanidatamab's conditional approval in China.
• Received a $7.5 million option exercise fee from Bristol-Myers Squibb (BMS), indicating continued partnership value.
• Cleared IND application for ZW251, a first-in-class GPC3-targeting ADC, with Phase 1 studies planned for 2025, advancing the wholly-owned pipeline.
• Initiated a Phase 2 trial for zanidatamab in HER2-positive neoadjuvant and adjuvant breast cancer, expanding its potential indications.
• Maintained a strong cash position of $333.4 million, providing at least 12 months of funding for operations and capital expenditures.
• Evolving business strategy to a capital-efficient, partnership-driven model is expected to enhance long-term stockholder value and provide a sustainable funding source.

Negatives

• Interest income decreased to $3.4 million in Q2 2025 from $5.2 million in Q2 2024, due to reduced cash balances and lower average yields.
• The company continues to incur significant losses, with an accumulated deficit of $850.7 million as of June 30, 2025.
• Development of ZW220 has been paused to facilitate accelerated development of ZW251, indicating a reprioritization that delays one pipeline asset.
• Confirmatory trials are required for continued approval of zanidatamab in China and Europe, and failure to demonstrate clinical benefit could lead to revocation of conditional approvals.
• The company will require substantial additional funding beyond the next 12 months to support ongoing operations and long-term business plans.

Risks

• Limited number of product candidates still in preclinical or clinical development, with no guarantee of regulatory approval or timely progression.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes, with past results not predictive of future success.
• Product candidates may have undesirable side effects that could delay or prevent marketing approval or limit sales.
• Significant competition from more effective, safer, or less expensive products could negatively impact commercial opportunities.
• Zanidatamab or other approved product candidates may not achieve broad market acceptance among physicians, patients, and third-party payors.
• Inability to successfully use therapeutic platforms to build a pipeline of product candidates.
• Exposure to product liability lawsuits, which could result in substantial liabilities and limit commercialization efforts.
• Security breaches, data loss, and other disruptions could compromise sensitive information and expose the company to liability.
• Current and future legislation may increase the difficulty and cost of commercializing approved products and affect pricing.
• Incurred significant losses since inception and anticipates continued losses, with no guarantee of achieving or sustaining profitability.
• Requires substantial additional funding, which may not be available on acceptable terms, potentially leading to delays or cessation of development programs.
• Adverse effects from tax law changes on business and financial condition.
• Dependence on collaborative relationships with Jazz and BeOne for zanidatamab development and commercialization, with risks of non-success or termination.
• Reliance on third-party manufacturers for product candidate supply, which could lead to delays or impairments.
• Reliance on third parties to monitor, support, and conduct clinical trials, with risks of non-performance or delays.
• Inability to obtain, maintain, and enforce patent and trade secret protection for product candidates and related technology.
• Stock price volatility and potential decline below the price paid by stockholders.
• Delaware law and corporate bylaws might delay, discourage, or prevent a change in control or management.
• Qualifying as a smaller reporting company may make common stock less attractive to investors due to reduced reporting requirements.
• Failure to maintain an effective system of internal control over financial reporting could impact financial reporting accuracy and investor confidence.
• Holders of Exchangeable Shares are subject to additional risks, including lack of market liquidity and uncertain tax treatment.

Future Outlook

Zymeworks anticipates that its existing cash resources will fund operating and capital expenditure requirements for at least the next twelve months. The company expects to continue incurring losses for the foreseeable future as it increases research and development expenditures for its product candidates. The future strategy is evolving to anchor around anticipated royalty and milestone revenues from Ziihera in currently approved and potential future indications, supplemented by additional revenues from existing and new partnerships, aiming for a capital-efficient partnership business model. The company intends to remain disciplined with its R&D investment strategy, focusing on high-potential, innovative programs that align with this partnership-driven model. Top-line progression-free survival (PFS) data from the HERIZON-GEA-01 study of Ziihera is expected in Q4 2025. IND submission for ZW209 is expected in 1H 2026, and a non-U.S. regulatory filing for ZW1528 is expected in 2H 2026, with further IND applications for other candidates anticipated in 2027 and beyond.

Management Comments

• "We look forward to reporting on the top-line progression-free survival (PFS) data from the HERIZON-GEA-01 study of Ziihera expected in 4Q-2025."
• "We are optimistic about the prospects of ZW191 and we believe the design features and preclinical profile support the potential of ZW191 to target cancers with lower levels of FR."
• "We are encouraged by published research demonstrating the potential of targeting GPC3 with an antibody in HCC patients... and believe that ADC-based targeting of GPC3 could enable a novel and effective approach to treatment of HCC."
• "We have paused the preparations for the commencement of a Phase 1 study of ZW220 to help facilitate the accelerated development of ZW251. However, we believe ZW220 remains a highly differentiated, IND-ready asset with strong clinical, commercial, and partnership potential."
• "We expect to submit an IND to commence Phase 1 clinical studies for ZW209 in 1H-2026, with equivalent non-U.S. applications to be submitted thereafter."
• "We expect to submit a non-U.S. regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2H-2026, with further non-U.S. applications to be submitted thereafter."
• "We believe there is a compelling opportunity to anchor our future strategy around anticipated royalty and milestone revenues from Ziihera in currently approved indications and other potential future indications, with the potential for these revenues to be supplemented over time with additional potential revenues from our existing partnerships as well as new partnerships and collaborations formed from our wholly-owned research and development pipeline and other potential opportunistic investments."
• "If this focused, capital-efficient partnership business model is effectively implemented, we believe the anticipated royalty and milestone revenues could serve as both a longer-term funding source for our continued research and development operations and as a foundation from which to grow our self-contained royalty income over the longer term."
• "We intend to remain disciplined with our research and development investment strategy with respect to focusing resource allocation on high-potential, innovative programs that align with our partnership-driven business model, whether originating from our wholly-owned research and development pipeline or accessed externally."

Industry Context

Zymeworks operates in the highly competitive and rapidly evolving biopharmaceutical industry, specializing in novel, multifunctional biotherapeutics for cancer and autoimmune/inflammatory diseases. The company's strategy to leverage its proprietary platforms (Azymetric, Drug Conjugate Platforms, EFECT, ProTECT) for both internal pipeline development and strategic partnerships aligns with industry trends of seeking non-dilutive funding and accelerating clinical development through collaborations. The focus on ADCs and multispecific antibodies, particularly T-cell engagers, reflects a growing area of interest in oncology. The conditional approvals for zanidatamab in China and Europe, following accelerated approval in the US, demonstrate progress in a competitive HER2-targeted therapy market, where companies like Genentech (Roche) with Herceptin and Perjeta, and AstraZeneca/Daiichi Sankyo with Enhertu, are established players. The shift towards a capital-efficient, partnership-driven model is a common strategy for clinical-stage biotechs to manage high R&D costs and mitigate risks.

Comparison to Industry Standards

• Ziihera (zanidatamab) is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the United States, setting a new benchmark in this specific indication.
• ZW191's preclinical data, demonstrating strong activity across a range of FR-expressing patient-derived xenografts, including models with low levels of FR, suggests potential to unlock efficacy for ovarian cancer patients unable to receive Elahere (mirvetuximab soravtansine), which is approved only in FR-high platinum-resistant ovarian cancer (PROC).
• ZW191's HNSTD of 60 mg/kg in non-human primates presents a compelling profile, suggesting a potentially efficacious dose level in Phase 1, which compares favorably to other ADCs in development.
• ZW251's preclinical tolerability at doses up to 120 mg/kg in non-GLP non-human primate studies suggests potential for high doses in humans, which could be a benefit for HCC patients often challenged by liver impairment.
• ZW220's design, with a DAR-four format and Fc region mutations, aims to overcome challenges encountered with other NaPi2b-targeted ADCs like Lifa-V, UpRi, and XMT-1592, potentially offering a safer profile.
• ZW171's preclinical data demonstrated greater anti-tumor activity compared to benchmarks in MSLN-expressing tumor models and good tolerability up to 30 mg/kg in cynomolgus monkeys, indicating a differentiated profile among T-cell engagers.
• ZW209's innovative TriTCE design, leveraging obligate cis-T cell binding and conditional CD28 engagement, aims to prevent unintended T cell activation while enhancing tumor-targeted cytotoxicity, potentially offering differentiated long-term cytotoxicity compared to existing T-cell engagers.
• ZW1528's bispecific design, blocking IL-4, IL-13, and IL-33, offers a unique approach to respiratory inflammation, with preclinical studies showing superior blockade of cytokine-driven activation of human epithelial cells compared to anti-IL-4R mAb or anti-IL-33 clinical benchmarks mAbs.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings or claims that would reasonably be expected to have a material adverse effect on its business, financial condition, operating results, or cash flows.

Related Party Transactions

• On June 26, 2025, pre-funded warrants held by EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. (together EcoR1), a related party due to its beneficial ownership, were net exercised in full. As of June 30, 2025, no pre-funded warrants were outstanding.

Stakeholder Impact

• **Shareholders**: Potential for enhanced long-term value through a capital-efficient, partnership-driven business model and potential future share repurchases. Dilution risk from future equity financings remains. Increased revenue and reduced losses are positive for investor confidence.
• **Employees**: Continued investment in research and development programs, and potential organizational growth, may create opportunities. However, strategic shifts and reprioritizations (e.g., ZW220 pause) could impact specific teams.
• **Customers (Patients)**: Progress in clinical trials and regulatory approvals for product candidates like zanidatamab (Ziihera) offers new treatment options for difficult-to-treat diseases like HER2+ BTC. Continued development of wholly-owned pipeline aims to address unmet medical needs.
• **Strategic Partners (Jazz, BeOne, BMS, GSK, Daiichi Sankyo, J&J, Merck)**: Continued collaboration and achievement of milestones strengthen relationships and provide mutual benefits. The company's evolving strategy emphasizes partnerships as a core component of its business model.
• **Creditors**: Improved financial performance and a strong cash position enhance the company's liquidity and ability to meet short-term obligations, reducing credit risk.

Next Steps

• Report top-line progression-free survival (PFS) data from the HERIZON-GEA-01 study of Ziihera in Q4 2025.
• Commence Phase 1 clinical studies for ZW251 in 2025.
• Submit an IND to commence Phase 1 clinical studies for ZW209 in 1H 2026.
• Submit a non-U.S. regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2H 2026.
• Pursue additional IND applications for other product candidates in 2027 and beyond.
• Continue to evaluate various partnering and other strategic collaboration transactions for later-stage development of product candidates.
• Remain disciplined with research and development investment strategy, focusing on high-potential, innovative programs.
• Conduct confirmatory trials for zanidatamab in China and Europe to maintain conditional approvals.
• Continue to manage and potentially pursue additional reorganizations related to the Redomicile Transactions.

Key Dates

Recommendation

While Zymeworks reported significant revenue growth and a reduced net loss, primarily driven by milestone payments and initial royalties from its partnered zanidatamab program, the company continues to incur substantial losses and will require significant additional funding for its wholly-owned pipeline. The strategic shift towards a capital-efficient, partnership-driven model is prudent, but the long-term success of its wholly-owned assets remains uncertain, subject to clinical trial outcomes, regulatory approvals, and successful future collaborations. The pausing of the ZW220 program, while a reprioritization, highlights the inherent development risks. Investors should hold, monitoring the progress of confirmatory trials for zanidatamab and the advancement of the wholly-owned pipeline through partnerships.

Keywords

Biopharmaceutical, Oncology, Antibody Drug Conjugate, ADC, Bispecific Antibody, Multispecific Antibody Therapeutics, MSAT, T Cell Engager, TCE, HER2, Zanidatamab, Ziihera, Clinical Stage, Drug Development, Biologics, Cancer Treatment, Autoimmune Diseases, Inflammatory Diseases, SEC Filing, 10-Q